Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus TRIANEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus TRIANEX.
DEXACORT vs TRIANEX
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Triamcinolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Allergic disordersDermatologic diseasesEndocrine disordersGastrointestinal diseasesHematologic disordersNeoplastic diseasesNervous system disordersOphthalmic disordersRenal disordersRespiratory diseasesRheumatic disordersCOVID-19 (in hospitalized patients requiring supplemental oxygen)Cerebral edemaNausea and vomiting (chemotherapy-induced)Antiemetic prophylaxis
Allergic conditions: severe allergic rhinitis, asthma, atopic dermatitisRheumatic disorders: rheumatoid arthritis, osteoarthritis, acute gouty arthritisDermatologic diseases: psoriasis, eczema, contact dermatitisOphthalmic uses: uveitis, keratitisOff-label: intralesional treatment for keloids, macular degenerationOff-label: epidural injection for radicular pain
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
50 mg orally once daily.
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in severe hepatic impairment.
Hepatic via CYP3A4; also undergoes 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2) mediated metabolism.
Primarily hepatic via CYP3A4; undergoes reduction and conjugation to inactive metabolites.
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal elimination accounts for 20%; 10% metabolized to inactive metabolites.
Approximately 77% bound, primarily to corticosteroid-binding globulin (CBG) and albumin
98% bound primarily to albumin and alpha-1-acid glycoprotein.
0.8-1.0 L/kg (apparent Vd), indicating extensive tissue distribution
0.8 L/kg (range 0.7–0.9 L/kg), indicating extensive extravascular distribution with high tissue affinity.
Oral: approximately 80%; IM: nearly 100% (slow absorption)
Oral: 45% (range 40–50%) due to first-pass metabolism; IM: 100%.
No adjustment needed for GFR >10 mL/min; for GFR <10 mL/min, consider 50% dose reduction.
eGFR 30-89 mL/min: 50 mg every other day; eGFR <30 mL/min: 25 mg every other day.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or use with extreme caution.
Child-Pugh A: 50 mg daily; Child-Pugh B: 25 mg daily; Child-Pugh C: not recommended.
Oral/IV: 0.02-0.3 mg/kg/day in divided doses every 6-12 hours; maximum 9 mg/day.
1 mg/kg orally once daily (max 50 mg).
Start at lower end of dosing range (e.g., 0.75-3 mg/day) due to increased risk of osteoporosis and hyperglycemia; monitor bone density and glucose levels.
Start at 25 mg orally once daily; titrate based on tolerability.
None.
Corticosteroids may increase risk of infections, mask signs of infection, and cause adrenal suppression. Avoid live vaccines. Do not administer via epidural or intrathecal routes due to risk of serious neurologic events.
["Immunosuppression and increased susceptibility to infections","Adrenal suppression with prolonged use","Cushing's syndrome with chronic therapy","Osteoporosis with long-term use","Gastrointestinal perforation or bleeding","Psychiatric disturbances including mood swings, euphoria, or depression","Posterior subcapsular cataracts and glaucoma","Kaposi sarcoma","Negative nitrogen balance","Growth suppression in children","Thrombotic events","Concomitant use with live or live attenuated vaccines contraindicated"]
["Adrenal suppression with prolonged use","Increased susceptibility to infections","Osteoporosis and bone necrosis","Gastrointestinal perforation, especially in patients with inflammatory bowel disease","Cushing's syndrome with high doses","Glaucoma and cataracts with ophthalmic use","Hypothalamic-pituitary-adrenal axis suppression","Impaired wound healing"]
["Hypersensitivity to dexamethasone or any component","Systemic fungal infections","Administration with live or live attenuated vaccines","Idiopathic thrombocytopenic purpura (relative)","Peptic ulcer disease (relative)","Herpes simplex keratitis"]
["Hypersensitivity to triamcinolone or any component","Systemic fungal infections","Live or attenuated vaccine administration","Intrathecal or epidural administration (contraindicated due to risk of arachnoiditis)","Idiopathic thrombocytopenic purpura (for intramuscular use)","Active untreated infections"]
Data Pending Review
Data Pending Review
Avoid grapefruit and grapefruit juice as they may increase dexamethasone levels. Avoid excessive salt intake as glucocorticoids can cause fluid retention (though minimal with dexamethasone). Limit alcohol as it can increase risk of gastrointestinal side effects.
Avoid grapefruit and grapefruit juice as they may increase systemic exposure. Limit high-sodium foods to reduce fluid retention. Potassium-rich foods (bananas, oranges) may be needed to counteract hypokalemia; monitor potassium levels. Avoid alcohol as it may increase gastrointestinal irritation.
First trimester: Increased risk of cleft palate (odds ratio 1.3-3.3) and intrauterine growth restriction. Second/third trimester: Maternal corticosteroid use linked to preterm birth and low birth weight. Long-term exposure may increase risk of adrenal suppression in neonate.
First trimester: Risk of neural tube defects and cardiac malformations based on animal studies; human data limited. Second and third trimesters: Risk of fetal growth restriction, preterm birth, and potential neurodevelopmental effects. Avoid use unless benefits outweigh risks.
Limited data; M/P ratio not established. Primarily excreted in breast milk at low concentrations. Use caution due to potential growth suppression and interfering with endogenous corticosteroid production.
No published data on excretion in human breast milk; M/P ratio unknown. Due to potential for adverse effects, advise against breastfeeding during treatment or consider alternative therapy.
No specific dose adjustments required, but consider increased clearance in pregnancy; monitor clinical effect. Use lowest effective dose. May need to adjust dose in third trimester due to increased volume of distribution.
Increased clearance during second and third trimesters may require dose augmentation by 20-30% to maintain therapeutic levels. Postpartum dose reduction to prepregnancy levels with monitoring.
Category C
Category C
DEXACORT is a brand name for dexamethasone, a potent long-acting glucocorticoid. It has zero mineralocorticoid activity, making it suitable for conditions requiring high-dose glucocorticoid without salt retention. Crosses blood-brain barrier readily; used in cerebral edema and as antiemetic in chemotherapy. Taper dose to avoid adrenal insufficiency. Monitor for hyperglycemia, especially in diabetic patients. Can cause acute pancreatitis; consider in abdominal pain.
TRIANEX (triamcinolone) is a potent corticosteroid; use lowest effective dose and shortest duration to minimize systemic side effects. Avoid abrupt withdrawal after prolonged therapy. Monitor for signs of adrenal suppression, osteoporosis, and immunosuppression. For intra-articular injection, limit frequency to every 3-4 weeks per joint to avoid cartilage damage. Inhaled forms require mouth rinsing after use to prevent oral candidiasis.
Take exactly as prescribed; do not stop suddenly to avoid withdrawal symptoms such as fatigue, joint pain, and fever.Report any signs of infection (fever, sore throat) as this drug can mask symptoms.Avoid live vaccines while taking this medication.Monitor blood sugar if diabetic; may require adjustment of diabetes medications.Inform all healthcare providers including dentists that you are taking corticosteroid therapy.
Do not stop taking this medication suddenly; follow your doctor's tapering instructions.Take with food or milk to reduce stomach upset if using oral tablets.Report any signs of infection (fever, sore throat) or unusual bleeding/bruising.Avoid live vaccines while on this medication.Use inhaled form exactly as prescribed; rinse mouth with water after each use to prevent thrush.